<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21119">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831959</url>
  </required_header>
  <id_info>
    <org_study_id>EF-25</org_study_id>
    <nct_id>NCT02831959</nct_id>
  </id_info>
  <brief_title>Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)</brief_title>
  <official_title>Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, randomized controlled phase III trial, to test the efficacy,
      safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic
      radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to
      supportive treatment alone. The device is an experimental, portable, battery operated device
      for chronic administration of alternating electric fields (termed TTFields or TTF) to the
      region of the malignant tumor, by means of surface, insulated electrode arrays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAST PRE-CLINICAL AND CLINICAL EXPERIENCE:

      The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in
      in vitro and in vivo NSCLC pre-clinical models both as a single modality treatment and in
      combination with chemotherapies. TTFields have also shown to inhibit metastatic spread of
      malignant melanoma in in vivo experiment.

      In a pilot study, 42 patients with advanced NSCLC who had had tumor progression after at
      least one line of prior chemotherapy, received pemetrexed together with TTFields (150 kHz)
      applied to the chest and upper abdomen until disease progression (Pless M., et al., Lung
      Cancer 2011). Efficacy endpoints were remarkably high compared to historical data for
      pemetrexed alone.

      In addition, a phase III trial of Optune® (200 kHz) as monotherapy compared to active
      chemotherapy in recurrent glioblastoma patients showed TTFields to be equivalent to active
      chemotherapy in extending survival, associated with minimal toxicity, good quality of life,
      and activity within the brain (14% response rate) (Stupp R., et al., EJC 2012). Finally, a
      phase III trial of Optune® combined with maintenance temozolomide compared to maintenance
      temozolomide alone has shown that combined therapy led to a significant improvement in both
      progression free survival and overall survival in patients with newly diagnosed glioblastoma
      without the addition of high grade toxicity and without decline in quality of life (Stupp
      R., et al., JAMA 2015).

      Applying TTFields at 150 kHz to the brain for the treatment of 1-5 brain metastasis from
      NSCLC using the NovoTTF-100M device has been demonstrated to be safe in a pilot study, where
      patients were randomize after local therapy of their brain metastasis by neurosurgery and/or
      stereotactic radiosurgery to receive either NovoTTF-100M treatment or supportive care alone.
      Eighteen (18) patients have been enrolled in the study. There have been no device-related
      serious adverse events (SAE) reported to date (Brozova H., et al., Neuro Oncol 2016).

      DESCRIPTION OF THE TRIAL:

      All patients included in this trial are patients with 1-10 supratentorial brain metastases
      from NSCLC which are amenable to stereotactic radiosurgery (SRS). In addition, all patients
      must meet all eligibility criteria.

      Eligible patients will be randomly assigned to one of two groups:

        1. Patients undergo SRS followed by TTFields using the NovoTTF-100M System

        2. Patients undergo SRS alone and receive supportive care.

      Patients in both arms of the study may receive systemic therapy for their NSCLC at the
      discretion of their treating physician.

      Patients will be randomized at a 1:1 ratio. Baseline tests will be performed in patients
      enrolled in both arms. If assigned to the NovoTTF-100M group, the patients will be treated
      continuously with the device until second cerebral progression.

      On both arms, patients who recur anywhere in the brain will be offered one of the following
      salvage treatments (according to local practice) including, but not limited to:

        -  Surgery

        -  Repeat SRS

        -  Whole brain radiotherapy (WBRT)

      Patients on the control arm will be offered to cross over to the NovoTTF-100M arm of the
      study and receive TTFields after salvage therapy for second cerebral progression if the
      investigator believes it is in the best interest of the patient and patient agrees.

      SCIENTIFIC BACKGROUND:

      Electric fields exert forces on electric charges similar to the way a magnet exerts forces
      on metallic particles within a magnetic field. These forces cause movement and rotation of
      electrically charged biological building blocks, much like the alignment of metallic
      particles seen along the lines of force radiating outwards from a magnet.

      Electric fields can also cause muscles to twitch and if strong enough may heat tissues.
      TTFields are alternating electric fields of low intensity. This means that they change their
      direction repetitively many times a second. Since they change direction very rapidly (150
      thousand times a second), they do not cause muscles to twitch, nor do they have any effects
      on other electrically activated tissues in the body (brain, nerves and heart). Since the
      intensities of TTFields in the body are very low, they do not cause heating.

      The breakthrough finding made by Novocure was that finely tuned alternating fields of very
      low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in
      the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are
      multiplying, TTFields cause electrically-charged cellular components of these cells to
      change their location within the dividing cell, disrupting their normal function and
      ultimately leading to cell death.. In addition, cancer cells also contain miniature building
      blocks which act as tiny motors in moving essential parts of the cells from place to place.
      TTFields interfere with the normal orientation of these tiny motors related to other
      cellular components since they are electrically-charged as well. As a result of these two
      effects, tumor cell division is slowed, results in cellular death or reverses after
      continuous exposure to TTFields.

      Other cells in the body (normal healthy tissues) are affected much less than cancer cells
      since they multiply at a much slower rate if at all. In addition TTFields can be directed to
      a certain part of the body, leaving sensitive areas out of their reach. Finally, the
      frequency of TTFields applied to each type of cancer is specific and may not damage normally
      dividing cells in healthy tissues.

      In conclusion, TTFields hold the promise of serving as a brand new treatment for brain
      metastases from NSCLC with very few side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first cerebral progression</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neurocognitive failure</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by cognitive decline on a battery of tests: Hopkins Verbal Learning Test (HVLT-R) free recall, delayed recall, and delayed recognition; Controlled Oral Word Association Test (COWAT); and Trail Making Tests (TMT) Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response in the brain</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second cerebral progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first and second cerebral progression evaluated in two cohorts, 1-4 brain metastases and 5-10 brain metastases.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cerebral progression at 2, 4, 6, 8, 10, 12 months</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial progression free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant progression in the supratentorial region</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline in cognitive function at 2, 4, 6, 8, 10, 12 months</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by HVLT-R free recall, delayed recall, and delayed recognition; COWAT; and TMT Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive failure-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Defined from the date of first SRS treatment to neurocognitive failure (as measured by HVLT-R free recall, delayed recall, and delayed recognition; COWAT; and TMT Parts A and B) or death (whichever occurs first), censored at the last neurocognitive assessment on which the patient was reported alive without neurocognitive failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using the EORTC QLQ C30 with BN20 addendum</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity during NovoTTF-100M treatment based on incidence and severity of treatment emergent adverse events as evaluated using the CTCAE version 4.0</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Brain Metastases From Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>NovoTTF-100M device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-100M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-100M device</intervention_name>
    <arm_group_label>NovoTTF-100M device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Standard of Care</intervention_name>
    <arm_group_label>Best Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age and older

          2. Life expectancy of ≥ 3 months

          3. New diagnosis of brain metastases from a histologically or cytologically confirmed
             primary or metastatic NSCLC tumor within 5 years of registration on the study. If the
             original histological proof of malignancy is greater than 5 years, then pathological
             confirmation is required (i.e.: from extra-cranial or intracranial disease).

          4. Karnofsky performance status (KPS) ≥ 70

          5. Graded Prognostic Assessment (GPA) score ≥ 2.0

          6. 1 inoperable brain metastasis or 2- 10 brain lesions per screening MRI, confirmed by
             contrast enhanced MRI amenable to SRS according to the following criteria:

               1. largest tumor volume &lt; 10 cc

               2. longest tumor diameter &lt; 3 cm

               3. Cumulative volume of all tumors ≤ 15 cc

          7. At least one measurable lesion per RANO-BM (Response Assessment in Neuro-Oncology
             Brain Metastases) Criteria for brain metastasis

          8. Patients must be receiving optimal therapy for their extracranial disease according
             to local practice at each center. Patients may continue on systemic therapy while
             receiving TTFields.

          9. Able to operate the NovoTTF-100M device independently or with the help of a caregiver

         10. Clinical trials prior to enrollment are allowed, as long as no brain directed therapy
             was included (current treatment trials are exclusionary)

        Exclusion Criteria:

          1. Patients who are known to have somatic tumor mutations in the following genes, for
             which targeted agents are available that directly affect the treatment of brain
             metastasis: Anaplastic lymphoma kinase (ALK), epidermal growth factor receptor
             (EGFR), ROS-1 proto-oncogene, and proto-oncogene B-RAF

          2. Patients who have a single, operable brain metastasis

          3. Patients with significant edema leading to risk of brain herniation

          4. Patients with midline shift &gt; 10mm

          5. Patients with intractable seizures

          6. Infratentorial metastases

          7. Leptomeningeal metastases

          8. Recurrent brain metastases or brain metastases previously treated with surgery and/or
             radiosurgery and/or brain radiotherapy

          9. Prior surgical resection or WBRT for newly diagnosed brain metastases (needle biopsy
             for diagnosis establishment is allowed)

         10. Severe comorbidities:

               1. Clinically-significant inadequate hematological, hepatic and renal function,
                  defined as: Neutrophil count &lt; 1.5 x 10 9/L and platelet count &lt; 100 x 10^9/L;
                  bilirubin &gt; 1.5 x upper limit of normal (ULN); aspartate transaminase (AST)
                  and/or alanine aminotransferase (ALT) &gt; 2.5 x ULN or &gt; 5 x ULN if patient has
                  documented liver metastases; and serum creatinine &gt; 1.5 x ULN

               2. History of significant cardiovascular disease unless the disease is well
                  controlled. Significant cardiac disease includes second/third degree heart
                  block; significant ischemic heart disease; poorly controlled hypertension;
                  congestive heart failure of the New York Heart Association (NYHA) Class II or
                  worse (slight limitation of physical activity; comfortable at rest, but ordinary
                  activity results in fatigue, palpitation or dyspnea).

               3. History of arrhythmia that is symptomatic or requires treatment. Patients with
                  atrial fibrillation or flutter controlled by medication are not excluded from
                  participation in the trial.

               4. History of cerebrovascular accident (CVA) within 6 months prior to randomization
                  or that is not stable

               5. Active infection or serious underlying medical condition that would impair the
                  ability of the patient to received protocol therapy

               6. History of any psychiatric condition that might impair patient's ability to
                  understand or comply with the requirements of the study or to provide consent

         11. Implantable electronic medical devices in the brain

         12. Known allergies to medical adhesives or hydrogel

         13. Currently pregnant or breastfeeding

         14. Concurrent brain directed therapy (beyond SRS and NovoTTF-100M as per protocol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minesh Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Cancer Institute, Miami FL USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center, Houston TX USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinai Gondi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Medicine Cancer Center, Warenville IL USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghazala Kabani</last_name>
    <email>patientinfo@novocure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Deakle</last_name>
      <email>mdeakle@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Messer</last_name>
      <email>amesser@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Fiveash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85170</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Canamar</last_name>
      <phone>520-626-6515</phone>
      <email>rcanamar@uacc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Hani Babiker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandy Leong</last_name>
      <phone>323-442-7532</phone>
      <email>Sandyleo@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Luz</last_name>
      <phone>310-423-5379</phone>
      <email>Luz.Felix@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Jethro Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinah Chung</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Jose Carrillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha French</last_name>
      <phone>714-734-6200</phone>
      <phone_ext>40838</phone_ext>
      <email>Martha.French@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Venita Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern CT</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micah Sy</last_name>
      <phone>203-333-1151</phone>
      <email>MSy@anscneuro.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Blondin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Andrews, RN</last_name>
      <phone>352-273-7981</phone>
      <email>sarah.andrews@neurosurgery.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>David Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gonzalez-Salas</last_name>
      <phone>786-527-8112</phone>
      <email>jessicag1@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Minesh Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Brain Tumor Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Elkins</last_name>
      <phone>404-605-2050</phone>
      <email>Shirley.Elkins@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Adam Nowlan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Mendelke</last_name>
      <phone>312-695-1383</phone>
      <email>anne.mendelke@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Priya Kumthekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabe Pugel</last_name>
      <phone>773-702-5928</phone>
      <email>gpugel@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Rimas Lukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CDH-Delnor Health System</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Smith, MS, CCRC</last_name>
      <phone>603-352-5360</phone>
      <email>Donald.Smith@CadenceHealth.Org</email>
    </contact>
    <investigator>
      <last_name>Vinai Gondi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare Cancer Care Center</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darla Hehman, RN</last_name>
      <phone>859-301-5473</phone>
      <email>darla.hehman@stelizabeth.com</email>
    </contact>
    <investigator>
      <last_name>Robert Albright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hargis</last_name>
      <phone>502-217-5244</phone>
      <email>erika.hargis@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Burton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Henry</last_name>
      <phone>504-842-8769</phone>
      <email>jehenry@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Marcus Ware, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanne Ianniello</last_name>
      <phone>617-636-2883</phone>
      <email>LIanniello@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Suriya Jeyapalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Ng</last_name>
      <phone>617-667-1832</phone>
      <email>cng2@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulette Palazzolo</last_name>
      <phone>248-672-7745</phone>
      <email>paulette.palazzolo@21co.com</email>
    </contact>
    <investigator>
      <last_name>Vito John Antonucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Nasseff Neuroscience Institute ANW Brain Tumor Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Hultman</last_name>
      <phone>612-863-3308</phone>
      <email>Meghan.hultman@allina.com</email>
    </contact>
    <investigator>
      <last_name>John Trusheim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Sieckowski</last_name>
      <phone>612-626-4495</phone>
      <email>ksieczko@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Almarie Coleman</last_name>
      <phone>(612)-624-5949</phone>
      <email>colem258@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Emil Lou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Buroker</last_name>
      <phone>507-293-0624</phone>
      <email>Buroker.Justine@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weil Cornell Medical College/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda De Laurentiis</last_name>
      <phone>646-962-9349</phone>
      <email>amd9041@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Scheff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabelle Germano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nyph/Cumc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Cieremans</last_name>
      <phone>212-304-5570</phone>
      <email>dc3195@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Teri Kreisl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Coghill</last_name>
      <phone>252-744-5723</phone>
      <email>coghilll@ecu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Wetherington</last_name>
      <phone>252-744-5687</phone>
      <email>wetheringtona16@ecu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Clinton Leinweber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Coe</last_name>
      <phone>336-713-6505</phone>
      <email>scoe@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Black</last_name>
      <phone>336-716-9342</phone>
      <email>jhblack@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chelsie Derr</last_name>
      <phone>570-271-6590</phone>
      <email>cmderr1@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanna Frangos</last_name>
      <phone>215-615-4186</phone>
      <email>Suzanne.frangos@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Brem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Steven Toms, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Adams, CCRP</last_name>
      <phone>910-683-0055</phone>
      <phone_ext>63005</phone_ext>
      <email>raadams@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Ballo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Cox</last_name>
      <phone>713-792-4928</phone>
      <email>vcox@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jing Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Salas</last_name>
      <phone>806-725-8068</phone>
      <email>ssalas@covhs.org</email>
    </contact>
    <investigator>
      <last_name>Paul Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dedra Preece, CRC</last_name>
      <phone>254-771-4826</phone>
      <email>dedra.preece@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ekokobe Fonkem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of VA Health Sciences Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Farrar, BS</last_name>
      <phone>434-982-6455</phone>
      <email>jcf6k@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Sheehan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Health</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca M Lee</last_name>
      <phone>757-388-4393</phone>
      <email>rmlee1@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Wylie Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matt Lasowski</last_name>
      <phone>414-805-8375</phone>
      <email>mlasowski@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Connelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancercare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Saranya Kakumanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Al Gratton</last_name>
      <phone>579-685-8618</phone>
    </contact>
    <investigator>
      <last_name>Brian Yaremko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Notre-Dame Hospital CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Roberge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Muanza</last_name>
      <phone>(514)-340-8288</phone>
      <email>tmuanza@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Thierry Muanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T-2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Roy-Huneault</last_name>
      <phone>(514)-252-3400</phone>
      <phone_ext>3227</phone_ext>
      <email>lroyhuneault.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Pierre Chabot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anick Champous</last_name>
      <phone>(819)-346-1110</phone>
      <phone_ext>12811</phone_ext>
      <email>achampoux.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Mathieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95.</citation>
    <PMID>15126372</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.</citation>
    <PMID>19387848</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.</citation>
    <PMID>26658786</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, Kirson ED, Palti Y. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014 Oct;41 Suppl 6:S35-41. doi: 10.1053/j.seminoncol.2014.09.006.</citation>
    <PMID>25213867</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.</citation>
    <PMID>26670971</PMID>
  </reference>
  <reference>
    <citation>Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013 Sep;81(3):445-50. doi: 10.1016/j.lungcan.2013.06.025. Epub 2013 Jul 23.</citation>
    <PMID>23891283</PMID>
  </reference>
  <reference>
    <citation>Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun;16(6):e270-8. doi: 10.1016/S1470-2045(15)70057-4. Epub 2015 May 27. Review.</citation>
    <PMID>26065612</PMID>
  </reference>
  <reference>
    <citation>Brozova H, Lucas A, Salmaggi A, Vymazal J. COMET: A phase II randomized study of TTFields versus supportive care in non-small cell lung cancer patients with 1-5 brain metastases - initial safety results. Neuro Oncol. 2015 Nov; 17 (suppl 5): v46. doi:10.1093/neuonc/nov208.6</citation>
  </reference>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>July 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Treatment</keyword>
  <keyword>Minimal toxicity</keyword>
  <keyword>TTFields</keyword>
  <keyword>TTF</keyword>
  <keyword>Tumor Treating Fields</keyword>
  <keyword>Novocure</keyword>
  <keyword>SRS</keyword>
  <keyword>Stereotactic radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
